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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) and its associated treatments may affect all
aspects of patients’ health-related quality of life (HRQoL). Although the EORTC QLQ-H&N35 is regularly administered to
patients with HNSCC, there is a paucity of studies re-assessing the conceptual relevance of this patient-reported outcome
(PRO) measure from a patient perspective. Furthermore, the content validity of the EORTC QLQ-C30 has not been widely
documented in patients with recurrent and/or metastatic HNSCC. The objectives of this study were to understand
patients’ experiences of recurrent/metastatic HNSCC and its treatments, and to evaluate the conceptual relevance
and acceptability of the EORTC QLQ-C30 and QLQ-H&N35 from a patient perspective for use in clinical trials.
Methods: A literature review and clinician interviews were conducted to inform in-depth semi-structured
telephone interviews with US patients who had received treatment for recurrent and/or metastatic HNSCC
in the preceding 12 months. Interview transcripts were analysed thematically using ATLAS.ti v7; patient quotes were
coded to identify concepts and themes to develop a conceptual model of HNSCC experience.
Results: Fourteen patients were interviewed (71% male, aged 35–84 years). Patients reported few symptoms pre-
diagnosis including neck lump/swelling (n = 7/14, 50%) and/or difficulty swallowing (n = 3/14, 21%). Treatments
generally comprised surgery and chemotherapy and/or radiotherapy. A number of side effects from all treatments
were reported. Numbness, difficulty speaking and pain were the most reported side effects of surgery (n = 4/8, 50%);
weight loss and fatigue were the most reported side effects of chemotherapy and/or radiotherapy (n = 8/13, 61%). All
side effects negatively impacted patients’ HRQoL. Patients generally found the QLQ-C30 and QLQ H&N35 content to
be understandable and conceptually relevant; excessive mucous production and neuropathic symptoms were among
the suggested additions.
Conclusions: HNSCC and its diverse symptoms and treatments have a negative impact on many aspects of patients’
lives. A number of reported symptoms including difficulty speaking and swallowing, localised pain and fatigue may be
important for treatment benefit evaluation in clinical trials from a patient perspective. The QLQ-C30 and QLQ-H&N35
are generally relevant and suitable for use in clinical trials. However, some items could be amended/added to ensure
conceptual comprehensiveness of these measures.
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Background
Head and neck cancer is a collective term that covers
malignant tumours arising out of the oral cavity, pharynx,
larynx and other anatomic sub-sites. As one of the more
common cancers worldwide, head and neck cancer ac-
counts for over 500,000 new cases and nearly 300,000
deaths annually [1]. Squamous cell carcinoma subtype
is the most common form of head and neck cancer (over
90%) [2] and arises from various locations in the head and
neck region including the nasal and paranasal cavities,
nasopharynx, oral cavity, oropharynx, larynx and hypo-
pharynx [3]. Due to the diversity of the affected sub-sites,
head and neck squamous cell carcinoma (HNSCC) can
manifest in a wide variety of symptoms such as hoarse-
ness, dysphagia (swallowing difficulties), otalgia (earache)
and cervical adenopathy (swollen lymph nodes/glands in
the neck) [2].
The majority of patients newly diagnosed with HNSCC
present with potentially curable localised disease. Treat-
ment options for these patients include surgery, radiation
therapy, chemotherapy and biologic therapy. In patients
who develop recurrent and/or metastatic disease, palliative
treatment with systemic therapy is used in the majority of
cases although, immune therapy (e.g. anti-PD-1 antibodies
nivolumab and pembrolizumab) are a recently approved
treatment option [1].
Patients with HNSCC often experience significant mor-
bidity related to the cancer itself and its treatment, and
mortality rates are exceptionally high. Despite recent inno-
vations in surgical techniques, the delivery of radiation, and
systemic therapies, the prognosis of patients with locally
advanced disease at presentation is poor with a five-year
survival of 50%, and a median overall survival of one year
in patients with recurrent or metastatic disease [4, 5].
Importantly, symptoms from the tumour (such as pain
and difficulty swallowing) and its treatments often result
in significant physical impairment (e.g. loss of taste),
functional impairment (e.g. difficulty breathing, as well
as voice, speech and hearing impairment), and psychosocial
problems (e.g. depression, social isolation, and delays
returning to work); all of which can have a negative
impact on all aspects of patients’ health-related quality
of life (HRQoL) [2, 6–8]. Thus, assessing symptoms,
changes in physical, functional, and socio-psychosocial
impairment, as well as in overall HRQoL, particularly
within clinical trials, is necessary not only to evaluate
the impact of the disease and its treatments on patients’
lives, but also to make informed decisions on clinical care
and rehabilitative services for patients [7–9].
Disease, treatment and site-specific patient-reported
outcome (PRO) measures can be used alone, in combin-
ation with more general measures (e.g. the Short Form-36)
or with clinical assessments such as videofluroscopy for
swallowing [10], to assess the impact of HNSCC on
patients’ HRQoL and provide an accurate assessment of
changes in patient status [8, 9, 11]. Patient experience
can also be assessed through qualitative approaches in-
cluding open- or semi-structured interviews [11]. Not-
ably, patient-reported data can be implemented into
clinical practice to improve quality of care for patients
with HNSCC [7, 9, 12]. A large number of disease-specific
PRO measures are currently available for the assessment
of HRQoL in patients with HNSCC [7, 9]. PRO measures
vary significantly with respect to their development and
validation and no one specific measure has been clearly
identified as the gold-standard to assess HRQoL in the
HNSCC population [8, 9, 13]. Furthermore, our know-
ledge on which PRO measures may be most suitable to
capture the impact of HNSCC and its treatments on pa-
tients in a clinical trial setting is limited. Some work has
been conducted in the area of PROs in head and neck
clinical trials [14]; however, little research has been carried
out to assess specific measures suitability in the field. Fac-
tors to consider when selecting such a measure include
disease location, treatment, timing of assessment, clinical
setting, study purpose, the research question, and the psy-
chometric properties of the measure [7, 11]. However,
capturing what is important to patients with the disease,
such as the most relevant symptoms and aspects of func-
tioning, should also be considered when selecting a PRO
measure.
A number of head and neck cancer PRO measures are
commonly used in clinical trials including: the European
Organization for Research and Treatment of Cancer Qual-
ity of Life Questionnaire Head and Neck Module (EORTC
QLQ-H&N35) [15, 16], the Functional Assessment of Can-
cer Therapy-Head and Neck Subscale (FACT-HN) [17], the
University of Washington Head and Neck Cancer Ques-
tionnaire (UW-QOL) [18, 19] and the 9-item Disabilities of
the Arm, Shoulder, and Hand (Quick DASH-9) [20]. The
EORTC QLQ-H&N35 is a 35-item measure designed to as-
sess the HRQoL of patients with HNSCC in conjunction
with the general cancer-specific European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLQ-C30); it measures functional status
(e.g. physical, role, cognitive, emotional, social), well-being,
symptoms and side effects of treatment (both EORTC tools
can be found at:: http://groups.eortc.be/qol/eortc-qlq-c30)
[7, 8, 11, 15, 16]. The EORTC QLQ-H&N35 is one of the
most frequently used PRO measures in the clinical trial
setting [7] and is a carefully constructed, thoroughly tested
measure with a large body of evidence supporting its
psychometric properties [8, 15, 16]. Although the EORTC
QLQ-H&N35 is regularly administered in patients with
HNSCC [15, 16], there is a paucity of qualitative studies
re-assessing the conceptual relevance of this PRO measure
to patients in light of the U.S. Food and Drug Administra-
tion’s (FDA) PRO Guidance [21]. In addition, the content
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validity of the EORTC QLQ-C30 has not been widely
documented in patients with recurrent and/or meta-
static HNSCC, although efforts are underway in a large
sample of mixed-diagnosis cancer patients [22]. Similar
to other PRO measures, the EORTC QLQ-H&N35 has
its strengths and weaknesses, therefore recognising and
understanding these in the context of clinical trials is of
high relevance. Qualitative research to ensure patient input,
for example through patient interviews, may help identify
the concepts and questions that are most relevant to pa-
tients, and to bridge the gap between QoL research and
clinical practice [8]. The opportunity to discuss PRO mea-
sures such as the EORTC QLQ-C30 and QLQ-H&N35 at
length with patients is very valuable to assess how appropri-
ate these measures are to capture symptom impact and
HRQoL in patients with HNSCC.
The aims of this study were: i. to conduct qualitative
interviews (consisting of concept elicitation questions
and cognitive debriefing of the EORTC QLQ-C30 and
QLQ-H&N35) with patients who received treatment for
HNSCC in order to explore patients’ experience of HNSCC
and its treatments, and understand how these affect their
daily activities and functioning, and ii. to evaluate the con-
tent validity and relevance of the EORTC QLQ-C30 and
QLQ-H&N35 from a patient perspective. The output of
data to help answer aim (i) will aid in identifying specific
symptoms which may be important to measure in clinical
trials.
Methods
Literature review
To assess what is most important and relevant to patients
with HNSCC, a qualitative literature search was conducted
in the Medline and EMBASE databases to identify pub-
lished qualitative research in patients with HNSCC (details
are not reported in this study [search strategy can be found
in Additional file 1: Table S1]). In total, 25 studies were se-
lected and fully reviewed to identify potential measurement
concepts, develop a patient road map of HNSCC (Fig. 1),
depicting a broad overview of patient experience, which
can help inform qualitative interview guides [see Additional
file 1 for a reference list of included studies].
Medical expert interviews
Six qualified healthcare professionals (n = 3 from USA,
n = 3 from EU) with current experience of managing and
treating patients with HNSCC (medical oncologists, n = 4;
surgeon, n = 1; specialist research nurse, n = 1) took part
in a 60-min semi-structured telephone interview to con-
firm the clinical relevance of the patient road map and
identify additional measurement concepts, mentioned to
them by their patients, that they deemed important
enough to include in the patient road map. The interviews
were audio recorded and transcribed to allow in-depth
qualitative analysis. Data from these interviews were used
to develop a conceptual model.
Patient interviews
Patients were recruited from two specialist clinical
sites in the US (Vanderbilt-Ingram Cancer Centre and
Massachusetts General Hospital) and two specialist re-
cruitment agencies applying the eligibility criteria listed in
Table 1.
Ethics approval was obtained from the Institutional
Review Boards of Dana-Faber/Harvard Cancer Center
for Massachusetts General Hospital and Vanderbilt
University. Approval from an Independent Review Board
(New England IRB) was also obtained to allow advertise-
ment for additional patients through two specialist recruit-
ment agencies. All patients provided informed consent. All
data were anonymised and held confidentially.
A semi-structured interview guide was developed by
experienced qualitative researchers and approved by an
advisory board of clinical experts. The content of the
interview guide was based on information gathered from
different sources including the literature review con-
ducted in the disease area (see details in section above)
and the qualitative interviews with medical experts in
HNSCC.
The semi-structured interview guide was divided into
two parts: concept elicitation (which consisted of 6 main
questions, and a number of probes for each) and cogni-
tive debriefing (consisting of questions asking about the
instructions, recall and understanding for each of the
items in the included measures). The concept elicitation
section consisted of questions regarding patients’ disease
journey (e.g. symptoms experienced), from diagnosis to
treatment and its related effects. Open-ended questions
were used to avoid biased responses (example questions
can be seen in Additional file 1: Table S2).
The cognitive debriefing consisted of an item-by-item
assessment, to ask patients the relevance of each item
and their understanding of the question and wording for
the EORTC QLQ-C30 and QLQ-H&N35, in line with
good practice guidelines [23]. The overall instructions,
recall period and response options of the measures were
also discussed. Patients were asked to complete a paper
and pen version of the questionnaire using a ‘think aloud’
technique (i.e. patients vocalised their thoughts as they
read each question and selected an answer).
Eligible patients (see Table 1 for eligibility criteria) were
invited to participate in a 90-min interview. Telephone in-
terviews were advised by clinical experts to allow patients
to remain in their own home between treatments. Due to
the nature of the illness affecting vocal cords, speech, and
fatigue, patients were able to split the interview over 2–3
separate conversations where necessary; two patients took
part in interviews consisting of two different sittings.
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Patients received an honorarium to compensate for
their time involved in the study.
Telephone interviews were conducted in English lan-
guage between December 2014 and January 2017 by ex-
perienced qualitative researchers in two waves (Fig. 2).
Data analysis
All interviews were audio-recorded, transcribed verbatim,
and subject to thematic analysis [24] facilitated by ATLAS.ti
v7 qualitative data analysis software [25]. Each transcript
was read and codes were assigned to sections of text per-
taining to common concepts or themes.
Concept elicitation analysis
Descriptive codes were applied using thematic analysis
techniques. Codes were developed into concepts and
grouped into domains. Patient-reported concepts were
compared and contrasted. A conceptual model was de-
veloped using concepts identified from the patient and
clinical expert interviews. This consisted of a visual rep-
resentation of patient experience, including important
symptoms and side effects, impacts and potential rela-
tionships between them.
Cognitive debriefing analysis
Concepts identified during the cognitive debriefing section
of the interview were tabulated to provide an item-by-item
account of patient feedback. Framework coding identified
conceptual relevance, item interpretation, and appropriate-
ness of instructions, response scales, response options, and
recall period.
Fig. 1 Patients road map in HNSCC. Abbreviations: HNSCC, head and neck squamous cell carcinoma
Table 1 Eligibility criteria for research interviews
Inclusion criteria
• Male or female of any race
• Aged ≥18 years on the day of the research interview
• Confirmed diagnosis of recurrent and/or metastatic HNSCC (oral
cavity, oropharynx, hypopharynx, or larynx)
• Patient has received treatment for recurrent and/or metastatic
HNSCC in the past 12 months
• Patient has a WHO Performance Status of 0 or 1a
• Patient is willing to take part in a 90-min face-to-face interview (or
via Skype or telephone if face-to-face is not possible)
• In the opinion of the patient’s physician, patient has the cognitive,
reading and linguistic capacities sufficient to allow her/him to
actively participate in a 90-min interview
• Patient speaks US-English as a first language and can read and write
US-English
• Patient has personally read, signed and dated a legally effective
written informed consent form prior to admission to the study
Exclusion criteria
• Patient has a significant psychiatric or physical co-morbid condition
that would, in the opinion of the patient’s physician, prevent his/her
participation in this study
• Patient is currently abusing drugs or alcohol or has done so in
12 months prior to interview
• Patient is unwilling or unable to comply with the requirements of
the study
Abbreviations: HNSCC head and neck squamous cell carcinoma, WHO World
Health Organization
aPerformance status = 0 indicates a patient who is fully active, able to carry on
all pre-disease performance without restriction; performance status = 1
indicates a patient who is restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or sedentary nature (e.g. light
housework, office work)
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Conceptual saturation
Interim analysis took place after the initial 12 qualitative
interviews (wave 1) to determine whether additional in-
terviews were required. Following completion of all the
interviews, the transcripts were split into two sets. Con-
cept elicitation segments of the interviews for Set 1 were
compared with those for Set 2 to identify any new con-
cepts that may have arisen in Set 2. Conceptual satur-
ation was considered to be attained if no new concepts
emerged in Set 2 from the spontaneously elicited con-
cepts, and therefore, no new information would be ob-
tained from additional qualitative data [26]. When a new
concept emerged, a retrospective review of previous in-
terviews was conducted to ensure that this concept was
not overlooked. All results and data analysis were reviewed
by the advisory board of clinical experts, developed specific-
ally for this study, to ensure the results were deemed clinic-
ally relevant.
Results
In total, 14 patients were interviewed; their demographic
and clinical characteristics are summarised in Table 2. A
diverse range of age, tumour location, time since diagno-
sis and previous treatments were captured; however, the
sample comprised only Caucasian patients, the majority
of whom had received higher education. Saturation was not
met after review of the first wave of interviews; therefore,
further interviews were performed. Following these add-
itional interviews, however, data saturation was deemed to
be achieved [presented in Additional file 1: Table S3] be-
cause the majority of concepts (especially impact concepts)
arose in the first set of interviews. There were some con-
cepts (such as difficulty chewing, ear pain, and headaches)
that were outlined in the conceptual model, but described
only by clinicians, not patients. For the concepts (such as
symptoms of fever, hearing problems, and impotence) that
arose only in the second set, nearly all were only mentioned
once; highlighting the variability of how HNSCC presents.
Interviews allowed in-depth, rich data to be obtained
providing a comprehensive insight into the HNSCC
patient experience.
Concept elicitation
The analysis of the concept elicitation data, combined
with input from the qualitative literature and medical
experts, led to the development of a conceptual model
summarising the experience of patients with HNSCC in
terms of measurement concepts and appropriate overarch-
ing themes. The conceptual model can be used to guide po-
tential areas suitable for patient-reported measurement,
and confirm content validity of patient-reported question-
naires. As demonstrated in Fig. 3, the patient experience of
HNSCC could be segmented into pre-diagnosis signs and
symptoms, emotional and psychological impacts of receiv-
ing a diagnosis, side effects due to various treatments, and
overall impact on patients’ life in addition to emotional and
psychological wellbeing.
During the concept elicitation part of the interview,
patients were asked to describe their experience of HNSCC,
including what symptoms they experienced, what lead
them to get medical input, and how their diagnosis affected
them. Prior to diagnosis, the most commonly reported
signs or symptoms of HNSCC were lumps or swelling
in the neck (n = 7, 50%) or difficulty swallowing (n = 3,
21%):
“Basically when I was first diagnosed I had a lump on
my neck, on my right hand side of my neck. I noticed it
for maybe two months, it did not bother me, did not
hurt.” (01–06-M-57)
“I first had a … difference in my swallow.” (01–04-M-59)
These problems negatively impacted patients ability to
eat/drink and speak. Upon receiving a diagnosis of HNSCC,
patients reported feeling shocked, surprised and/or disbe-
lief. One patient expressed great frustration at the length of
Fig. 2 Wave structure of patient interviews. Abbreviations: CD cognitive debrief, CE concept elicitation; mins, minutes, EORTC QLQ-C30 European
Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire, EORTC H&N35 European Organisation for Research and
Treatment of Cancer, Quality of Life Questionnaire Head and Neck Module. Note: Wave 2 consisted of a smaller number of participants due to
conceptual saturation being achieved
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time it took for his (or her) diagnosis to be reached. An-
other described feelings of guilt for not having his (or her)
symptom (lump on tongue) evaluated sooner; the same pa-
tient also reported feeling overwhelmed after receiving his
(or her) diagnosis. An overview of the signs and symptoms
experienced by patients prior to treatment are outlined in
Table 3.
Patients were also asked about the treatment that they
had received for their HNSCC. Thirteen patients received
both chemotherapy and radiation treatment, seven of which
also received surgery; the remaining patient had only re-
ceived surgical treatment (Table 2). Due to the range of
treatments received, the specific source of various side
effects and treatment-related impacts was difficult for
patients to attribute. However, since surgery was often
an isolated event with regards to other treatments, the
side effects or complications of this were more readily
discernible. All patients who underwent surgery in combin-
ation with other treatments or alone (n = 8) experienced
some side effects resulting from their surgery; numbness
around the site of surgery (mouth, cheek, tongue and neck;
n = 4, 50%), post-surgical pain (n = 4, 50%) and difficulty
speaking (n = 4, 50%) were the most frequently reported
(Table 4).
“I had 20 staples in my neck and I woke up in a lot of
pain … I couldn’t talk. My friends would call and
family to see how I was and it was very difficult
talking on the phone initially” (01–14-F-61)
Side effects resulting from chemotherapy and/or radi-
ation included tiredness/fatigue/exhaustion (n = 8, 61%),
taste problems (n = 6, 46%), nausea (n = 5, 38%) and loss of
appetite (n = 2, 15%), all of which may have contributed
towards the significant weight loss experienced by many
patients (n = 8, 61%). Patients also reported various oral
Table 2 Demographic and clinical characteristics of interviewed
patients to be inserted
Characteristic Total, n (%) N = 14
Gender, n (%)
Male 10 (71)
Female 4 (29)
Age range, years, n (%)a
< 55 2 (14)
55–64 7 (50)
65–74 3 (21)
75–84 2 (14)
Ethnicity, n (%)
Caucasian or white 14 (100)
Education, n (%)a
Bachelor/graduate degree or higher 10 (71)
High school diploma or equivalent 3 (21)
Missing data 1 (7)
Work status, n (%)
Full/part- time paid 7 (50)
Retired 4 (29)
Other 3 (21)
Tumour Location, n (%)a
Oral cavity 6 (43)
Larynx 2 (14)
Oropharynx 3 (21)
Hypopharynx 2 (14)
Nasopharynx 1 (7)
Cancer status, n (%)
Metastatic 10 (71)
Recurrent 4 (29)
Tumour progression during or after treatment
Yes 4 (29)
No 10 (71)
WHO performance status, n (%)b
0 7 (50)
1 7 (50)
Time since diagnosis, n (%)
3–6 months 1 (7)
Within last 12 months 2 (14)
1–2 years 7 (50)
> 2 years 4 (29)
Treatment history, n (%)
Surgery only 1 (7)
Chemotherapy and radiation 6 (43)
Radiation, chemotherapy and surgery 7 (50)
Additional treatmentsc 2 (14)
Table 2 Demographic and clinical characteristics of interviewed
patients to be inserted (Continued)
Characteristic Total, n (%) N = 14
Comorbidities, n (%)
Hypertension 3 (21)
Heart disease 2 (14)
Respiratory disease 1 (7)
Cancer (other than H&N) 1 (7)
Other 2 (14)
Abbreviations: H&N head and neck. WHO World Health Organization
aPercentages do not total 100% due to rounding
bWHO performance status 0 = fully active, able to carry on all pre-disease
performance without restriction; WHO performance status 1 = restricted in
physically strenuous activity but ambulatory and able to carry out work of a
light or sedentary nature, e.g., light house work, office work)
cAdditional treatments were: immunotherapy; pembrolizuamb or nivolumab
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side effects including alterations in their sense of taste and
changes to saliva production e.g. sticky saliva/excessive mu-
cous (Table 4). Pain was reported mainly in relation to pain
at radiation sites; however, one patient reported experien-
cing pain after chemotherapy:
“After it was done I felt a little bit of pain…it was
pain, but I guess it didn’t last too long, but it was still
there.” (01–10-M-35)
More readily distinguishable side effects deemed specific
to radiation included soreness (n = 5, 38%), burns (n = 5,
38%) and dry skin at the site of radiation (n = 4, 31%):
“The radiation you do have… your neck gets burned
almost like a sunburn” (01–03-M-55)
Impacts on emotional and psychological wellbeing
throughout the course of patients’ HNSCC were also
readily discussed. Patients reported feeling fearful for
the future and their families, and feeling depressed and
upset. The four patients who had experienced recur-
rence described feeling helpless, overwhelmed, and
scared upon receipt of this news.
“I felt really very bad when I found out the cancer had
come back, just hopeless” (01–15-F-32)
In the patient sample, only two patients had received
immunotherapy as part of a clinical trial and they did
not attribute any specific side effects to this treatment
type.
Cognitive debriefing
During the second part of the interview, patients
were asked to complete the EORTC QLQ-C30 and
QLQ-H&N35 aloud, and provide their thoughts. The
majority of patients (n = 12, 86%) reported that the
EORTC QLQ-C30 and QLQ-H&N35 were suitable and
easy to complete. The key findings from the cognitive
debriefing interviews are presented in Table 5 and elabo-
rated on subsequently.
Conceptual relevance
Every item of the EORTC QLQ-C30 and QLQ-H&N35
was described as relevant by at least one patient regard-
ing their individual experience. While the majority (n =
12, 86%) of patients felt that the questionnaires covered
the most important aspects of their disease experience,
two patients suggested adding items relating to side ef-
fects they had experienced: excessive mucous production
and neuropathic symptoms.
“You could probably ask about … nerves, neuropathy,
whether your feet or hands or fingers are still normal
Fig. 3 Conceptual model of HNSCC patient experience. The conceptual model was cross-checked with the results of the medical expert
interviews. Additional concepts reported by the experts were added to the conceptual model where these were not reported by patients during
the concept elicitation interviews (highlighted in the grey boxes). Note: Although immunotherapy is included in the conceptual model, data on
side effects experienced is limited by the small number of patients (n = 2) receiving this treatment (as part of a clinical trial) and by the fact that
they did not attribute any specific side effects to this treatment type
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Table 4 Side effects of surgery and chemotherapy and/or radiotherapy in patients with HNSCC
Surgery Chemotherapy and/or radiotherapy
Side effect Reported by (N = 8) Side effect Reported by (N = 13)
S P Total S P Total
Numbness 1 3 4 Weight loss 1 7 8
Difficulty speaking 4 4 Tiredness/fatigue/exhaustion 3 5 8
Pain 2 2 4 Taste problems 6 6
Swelling 1 2 3 Pain 3 3 6
Dry mouth 2 2 Dry mouth/lack of saliva 5 5
Soreness/discomfort 2 2 Nausea 5 5
Weakness 2 2 Hair loss 1 1 2
Tired/fatigue/exhaustion 2 2 Vomiting 2 1 3
Swallowing problems 1 1 2 Weakness 3 3
Constipation 1 1 Breathing problems 2 2
Impact on range of movement 1 1 Excessive mucous 2 2
Taste problems 1 1 Loss of appetite/eating less 2 2
Tooth damage/removal 1 1 Sticky saliva 2 2
Weight loss 1 1 Fever 1 1
Scarring 1 1 Impotence 1 1
Abbreviations: N total number of patients reporting side effects, P reported when prompted, S reported spontaneously
Table 3 Overview of signs and symptoms experienced by patients prior to treatment
Symptom Reported Example quote
S P Total
Lumps; head/neck 6 6 • “Basically when I was first diagnosed I had a lump on my neck, on my right hand side of my neck.
I noticed it for maybe two months, it did not bother me, did not hurt.” (01–06-M-57)
Difficulty/difference in swallowing 3 3 • “I first had a… noticed a difference in my swallow... it was something that was different.”
(01–04-M-59)
Pain 1 1 2 • ”.. my mouth it would hurt and I knew there was something wrong.” (01–07-F-66)
Swollen lymph nodes (neck) 2 2 • “…nothing else other than the visible swelling of the lymph nodes and no pain, nothing else.”
(01–03-M-55)
Tongue ulcer 1 1 • “Initially I had a sore on my tongue that didn’t heal so I was sent to an oral surgeon and then an ear,
nose and throat doctor.” (01–14-F-61)
Weight loss 2 2 • “I started losing weight but not a lot at that time... I’m watching my weight go down and going okay
but it wasn’t going down that much.” (01–07-F-66)
Change in voice 1 1 • “That would be going back to like a raspy throat like what I had prior to being diagnosed, I had this…
It would seem like my mouth was raspy and noticeably kind of different pitched.” (01–09-M-66)
Cough 1 1 • “I started to get a little more noticeable that I kept clearing my throat and coughing a little bit and so
I decided to go to the doctor’s thinking maybe there was an infection or something of that nature.”
(01–09-M-66)
Dry/peeling skin on the neck 1 1 • “It felt like when you go swimming and your skin dries out, that’s how my neck was feeling, every
two or three days or something like that.” (01–10-M-35)
Eating less 1 1 • “I told him I used to be somewhat hungry all three times of the day, but it’s shifted now to only two
times of the day.” (01–10-M-35)
Hearing problems 1 1 • “I was having hearing problems…so I went to an ENT. He ran some tests on me and then he said we
have a problem, we’re going to drill up and do a biopsy, and that’s when they found I have a
nasopharynx tumour.” (01–13-F-62)
Impact on range of movement 1 1 • “So my hands were throwing to a certain direction, but my eyes or my face wouldn’t turn in that
direction, just because of the neck drying out, slowing up, stiffen up.” (01–10-M-35)
Tiredness 1 1 • “I said I felt like I was getting enough sleep, but I still feel a little tired.” (01–10-M-35)
Abbreviations: P reported when prompted, S reported spontaneously
Degboe et al. Journal of Patient-Reported Outcomes  (2018) 2:33 Page 8 of 13
or tingly, numb, anything like that, because I think
that must happen quite a bit with chemo…” (01–
04-M-59)
“Yes, you need to expand on the mucous thing … it is
very discomforting” (01–03-M-55)
Interpretation and understanding
Patients were able to follow the instructions as intended
when completing the measure, although one patient sug-
gested that the instructions for the EORTC QLQ-C30
items could be improved by specifying that the question-
naire is concerned with aspects of health relating to can-
cer and its treatment, rather than ‘you and your health’.
Another patient was unsure if they should have responded
to the EORTC QLQ-H&N35 items specifically in refer-
ence to their treatment side effects.
“They are asking me to do a response to the questions
by circling the number that applies best to my
condition and my situation.” (01–05-M-57)
“…if it says something that closely relates to you … we
are interested about your treatment for cancer or your
treatment about a serious severe illness, then you
know that pinpoints it. Because if you think about it
health could be anything.” (01–10-M-35)
“But what I don’t understand is there might be
some things that have happened that are not
related to the surgery and so [do I] answer yes for
those, or...?” (01–11-M-62)
Whilst the majority of items were understood consist-
ently by all patients, some issues were apparent regarding
the wording of five items. The wording of Item 2 (‘Do you
have any trouble taking a long walk?’) was considered un-
clear by two patients as they felt that the item needed to be
more specific as to what a ‘long walk’ is. A similar opinion
was expressed for Item 3 (‘Do you have any trouble taking
a short walk outside of the house?’). Patients interpretation
of a ‘long’ and ‘short’ walk varied; ‘long’ could be considered
‘more than a mile’ or ‘over 5 minutes’, while short could be
considered ‘a block or so’ or ‘two doors down’.
“It’s confusing … I would say a distance or even a
timeframe … maybe you can say [a long walk is] a 20-
minute walk or a one mile walk.” (01–10-M-35)
Regarding Item 36 (‘Have you had problems swallow-
ing pureed food?’), one patient was unsure what consti-
tuted ‘pureed’ food.
“I don’t know what the difference is between solid food
and pureed food. Pureed food supposed to be like
apple sauce or something?” (01–10-M-35)
Table 5 Summary of cognitive debriefing findings
Consideration Findings Example quotes
Conceptual relevance • All items deemed relevant by patients
• Most key symptom/side effect and impact concepts
assessed, although some are missing (e.g. neuropathic
symptoms, excessive mucus production)
• “I: Is there anything important you feel that’s missing from
either of the questionnaires? 01–06-M-57: No.”
• “You could probably ask about there wasn’t anything really on
here about nerves, neuropathy, whether your feet or hands or
fingers are still normal or tingly, numb, anything like that, because
I think that must happen quite a bit with chemo…” (01–04-M-59)
Interpretation and
understanding
• Instructions well understood and consistently followed
• Items generally well understood and interpreted
consistently; problematic items included those assessing
a ‘long’ or ‘short’ walk, and “sticky saliva”; mainly
associated with the definitions of what these consisted of
• “They are asking me to do a response to the questions by circling
the number that applies best to my condition and my situation.”
(01–05-M-57)
• “That I just think it’s confusing... I would say a distance or even a
timeframe…maybe you can say a 20-min walk or a one mile walk.”
(01–10-M-35)
Response scale
and options
• Largely considered appropriate
• Patients with feeding tubes at the time of study
completion had difficulty responding to items related
to eating and swallowing
• “I: The response options; do you think they’re suitable?
The four response options? 01–14-F-61: Yes.”
• “I: That’s quite an important point you’ve brought up there,
obviously some of these are not relevant to you. Do you feel
that there should be an answer that says ‘not relevant’? Yes.”
(01–12-M-70)
Recall period • Recall employed for Items 1–5 varied, due to no
specified recall period
• The recall period of the remaining items was easily
understood but not always adhered to throughout
• “I: Again, the recall period, what recall period were you
thinking of? 01–15-F-32: Right now these are last week as well.”
• “The only comment I made at the beginning, being clear about the
timeframe one through five, and once you get past one through five
you understand. But I think that would be… you could go through
the first five questions and answer them with the wrong timeframe.”
(01–03-M-55)
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Three patients found the term ‘sticky saliva’ in Item 42
(‘Have you had sticky saliva?’) unclear.
“Sticky saliva, I don’t know what sticky saliva is, is
that just mucous or sticky saliva, what’s the
difference?” (01–04-M-59)
Furthermore, three patients struggled to correctly under-
stand Item 62 (‘Have you taken any nutritional supplements
[excluding vitamins]?’); two read the question as ‘including
vitamins,’ rather than excluding vitamins and one did not
know whether to include nutritional food within this.
Response scale and options
Overall, patients found the response options for the
QLQ-C30 and QLQ-H&N35 understandable and rele-
vant. However, two patients struggled with the response
options and reported trouble interpreting them for
their symptoms which included diarrhoea and vomiting
(Items 15–17).
“Yes, I think based on the questions they are asking I
think they are appropriate.” (01–05-M-57)
“Okay have you had diarrhoea? Well I’ve had loose
stools a couple of times but I haven’t had it constantly.
You know, so how do you answer it? …I mean because
you know sometimes things happen to you but not all
the time.” (01–07-F-66)
Patients with an assisted feeding tube (n = 3, 21%) felt
that none of the response options were applicable for
several items related to appetite, eating and swallowing
food (Items 13, 36–38, 49–52). One considered the
addition of a ‘Not relevant/Not applicable’ option to be
more appropriate.
“Right now I can’t have any food, it’s in my feeding
tube … that’s another non-answer because I don’t have
meals.” (01–13-F-62)
Recall period
Generally, the recall period was understood and used
correctly; however, two patients used it incorrectly, and
three patients suggested changes to help clarify the recall
for Items 1–5 of the EORTC QLQ-C30, which does not
specify a recall period. Patients varied greatly in the
timeframes they considered when answering these ques-
tions, from ‘now’ to ‘the last year and a half ’.
“…the only thing I would probably make clearer is in
your current timeframe maybe, those [first] five
questions, so you know its present.” (01–06-M-57)
For the remaining items, the minority of patients (n = 5,
36%) who did not use ‘the past week’ recall period were
often thinking back to their current or recent treatment
period. This is unlikely to be an issue when the measure is
issued during a clinical trial.
“I’m thinking of from treatment to now.” (01–07-F-66)
“I was averaging over this treatment.” (01–12-M-70)
Discussion
To our knowledge, this appears to be a novel qualitative
study aimed at exploring patients’ experiences of recurrent/
metastatic HNSCC and its treatments, and to evaluate the
conceptual relevance and acceptability of the EORTC
QLQ-C30 and QLQ-H&N35 from a patient perspective.
Other studies have assessed the use of these PRO mea-
sures, including assessing the QLQ-C30 for content valid-
ity [22, 27–30]; however, none of these studies appear to
have debriefed the PRO measures following an approach
similar to that used in this study [31]. Patients’ experiences
were depicted in the form of a conceptual model sec-
tioned into pre-diagnosis signs and symptoms, emotional
and psychological impact of receiving a diagnosis, side ef-
fects due to various treatments, and overall impact on pa-
tients’ life and emotional and psychological wellbeing.
This conceptual model highlights the impacts and burden
of HNSCC on patients some of which may be suitable to
capture through patient self-report.
Several PRO measures specifically designed for use in
patients with HNSCC are currently available, with the
EORTC QLQ-C30 and QLQ-H&N35 being the most
frequently used [7]. The wide and frequent use of these
PRO measures together with the changes in the treat-
ments for HNSCC over time justify a robust examin-
ation of their strengths and weaknesses and potential
adjustments to ensure accurate assessment. During the
development and initial validation of these European
Organization For Research And Treatment Of Cancer
(EORTC) measures, limited patient input and feedback
was sought [15, 16]. Unlike the initial validations, this
study incorporated cognitive interviewing techniques to
debrief both questionnaires, enabling a more thorough
understanding of their relevance and acceptability. Fur-
thermore, modern advances in therapy in addition to soci-
etal changes since the questionnaires’ development also
justify an updated debriefing. It is important to note that
an updated version of the EORTC QLQ-H&N35 is under
development (the QLQ-H&N43) [32–34]; however, the
final version was not available for consideration in this
study. The update of this PRO measure was felt advisable
given the deficits in the original EORTC head and neck
cancer module in relation to targeted and/or multimodal
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therapy [32, 34]. The preliminary revised module includes
17 additional items (a number of which were identified in
this study, such as “tingling or numbness in hands or
feet”) and one altered item; nine items of the H&N35 were
removed [32]. Prior to use in clinical trial, further debrief-
ing through in-depth cognitive interviewing will be war-
ranted once the update is finalised.
Results from this study suggest that all items were
deemed relevant by patients, however, neuropathic symp-
toms and excessive mucus production were cited as ‘miss-
ing’ concepts. The symptoms and impacts reported by
patients during this study may be used to inform the se-
lection and prioritisation of endpoints during clinical tri-
als. From the insight gained from the patients during this
study, it would appear that patients identified difficulty
speaking/slurred speech, difficulty swallowing (and there-
fore eating/drinking), localised pain, and fatigue as the
most significant physical impacts.
Although some new concepts arose in the second set
of data during qualitative analysis, they were usually
unique to the specific patient who reported them; this is
unsurprising due to the heterogeneity of tumour location
and disease experienced by the patient sample. Therefore,
saturation was deemed to be obtained. The appearance of
new concepts is not uncommon in studies such as this, and
it is important to use scientific judgement, including know-
ledge in the field, as well as consultation with experts to de-
termine how important any new concept is (e.g. is it minor,
technically unrelated, or an outlier) [35]. For this study, this
approach was followed and further judgement from the re-
search team and the advisory board of clinical experts de-
termined that additional data collection was not warranted.
The omission of elicited concepts (see Fig. 3) in the
EORTC questionnaires is notable, although a previous re-
view reports their content coverage as the widest of nine
HNSCC-specific questionnaires [13]. Despite this, it is
recognised that no single measure is ideal for all scenarios
and can fully assess every possible issue; the specific con-
text should be considered. For example, a recent paper
authored by several members of the FDA’s Center for
Drug Evaluation and Research proposed a focus on the
measurement of symptomatic adverse events, physical
function, and disease-related symptoms [36]. Any add-
itional treatment-related side effects of interest, but not
covered by the questionnaire, could be assessed through
selecting appropriate items from a bank such as the
Patient-Reported Outcomes version of the Common
Terminology Criteria for Adverse Events (PRO-CTCAE)
(e.g. its ‘numbness and tingling’ item to capture neuro-
pathic symptoms) [37]. Alternatively, PRO measures such
as the Patient Concerns Inventory incorporate an optional
free-text item [38].
The questionnaires were generally well understood. Spe-
cial care should be taken when administering the EORTC
QLQ-C30 and QLQ-H&N35 in patients with a feeding
tube, as issues were raised regarding the response options
for items related to eating and swallowing. The lack of a
‘not applicable’ response option may lead to inaccurate or
missing responses in this patient subgroup. This issue
should be explored further, especially as item 63 of the
questionnaire assesses the use of a feeding tube, thus
acknowledging that for many patients items about food
consumption will not be relevant. The recall period of the
questionnaires was also deemed suitable, however, the
omission of a defined recall period for the first five items
(forming the physical functioning scale) seems to be prob-
lematic and could introduce unwanted noise in the ob-
tained scores [21].
This study provides a considerable volume of rich data
directly elicited from patients with diversity in HNSCC
locations and other clinical characteristics, and uses the
input of several sources to yield a conceptual model.
The study findings are therefore generalisable to patients
with a similar presentation to the inclusion criteria pre-
sented in Table 1, i.e. those with a diagnosis of recurrent
and/or metastatic HNSCC who have received treatment
in the preceding 12 months. However, some limitations
of this study are to be acknowledged. The majority of
the interviewed patients were male and all were Caucasian;
hence, differences in experience are only present according
to these characteristics. The fact that the majority of inter-
viewed patients had received higher education is another
limitation in light of assessing item understanding; a greater
number of patients who had received lower education
would increase confidence in the generalisability of
these findings. In addition, there was limited opportunity
to understand the impacts and side effects associated with
immunotherapy; only two patients had received this (as
part of a clinical trial) and did not attribute any specific
side effects to this treatment type.
Conclusions
A HNSCC diagnosis and its diverse symptoms and
treatments may have a negative impact on many as-
pects of patients’ lives. This study has identified a num-
ber of symptoms, including difficulty speaking and
swallowing, localised pain, and fatigue, that may be im-
portant for treatment benefit evaluation in clinical trial
from the patient’s perspective. PRO measures are an
important source of data that can capture such impacts
to inform patient perception of treatment effectiveness,
the selection and prioritisation of endpoints during
clinical trials, as well as clinical care decision making.
Therefore, evidence to support the use of such measures
is very important. Furthermore, reflection from the pa-
tients’ perspective can be somewhat lacking once a ques-
tionnaire is established. The findings of this study support
the conceptual relevance of the EORTC QLQ-C30 and
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QLQ-H&N35, although additional concepts not included
in the questionnaires were cited by patients. While both
questionnaires were positively perceived by the majority of
patients, a minority of problematic items and recall issues
were identified. Thus, further research may be required to
confirm the suitability of any updated or amended meas-
ure. Additional clarification is also needed when adminis-
tering the questionnaires in patients with feeding tubes.
The EORTC QLQ-C30 and QLQ-H&N35 are the main-
stay of PRO measures for HRQoL in head and neck clin-
ical trials; however, researchers and clinicians should be
mindful of the potential downfalls of these measures, in-
cluding those identified in this study. Depending on the
clinical trial design, additional questionnaires may be re-
quired for higher precision in specific areas of interest but
also to cover the potential shortcomings from the patient
perspective identified in this qualitative study. A similar
approach to the work conducted in this study may be
helpful to ensure any additional questionnaires are rele-
vant and suitable for use.
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